Susie Jun

6.8k total citations · 5 hit papers
25 papers, 4.9k citations indexed

About

Susie Jun is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Susie Jun has authored 25 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Hematology and 8 papers in Genetics. Recurrent topics in Susie Jun's work include Bone health and treatments (15 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and Cancer Diagnosis and Treatment (6 papers). Susie Jun is often cited by papers focused on Bone health and treatments (15 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and Cancer Diagnosis and Treatment (6 papers). Susie Jun collaborates with scholars based in United States, Australia and Canada. Susie Jun's co-authors include Allan Lipton, Roger Dansey, Michelle Fan, Qi Jiang, Katia Tonkin, Guenther G. Steger, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Alison Stopeck and Ada Braun and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Susie Jun

25 papers receiving 4.8k citations

Hit Papers

Denosumab Compared With Zoledronic Acid for the Treatment... 2010 2026 2015 2020 2010 2011 2010 2012 2012 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
    2010 1.1k citations Alison Stopeck, Allan Lipton et al. Journal of Clinical Oncology profile →
  2. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
    2011 877 citations David H. Henry, Luís Costa et al. Journal of Clinical Oncology profile →
  3. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
    2010 516 citations David M. Thomas, Robert M. Henshaw et al. The Lancet Oncology profile →
  4. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
    2012 420 citations Allan Lipton, Karim Fizazi et al. European Journal of Cancer profile →
  5. Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
    2012 332 citations Daniel Branstetter, Scott D. Nelson et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susie Jun United States 15 3.7k 1.4k 1.2k 1.1k 1.1k 25 4.9k
Ada Braun United States 22 2.7k 0.7× 754 0.5× 834 0.7× 285 0.3× 749 0.7× 63 3.2k
Dirk J. Reitsma United States 15 5.5k 1.5× 1.6k 1.2× 1.3k 1.1× 202 0.2× 2.2k 2.1× 34 6.3k
Lawrence I. Karsh United States 21 1.8k 0.5× 1.8k 1.3× 397 0.3× 174 0.2× 783 0.7× 113 3.2k
Dimitra Gika Greece 30 2.3k 0.6× 345 0.3× 1.0k 0.8× 253 0.2× 229 0.2× 83 4.2k
Michael Rader United States 9 1.8k 0.5× 1.0k 0.7× 463 0.4× 141 0.1× 666 0.6× 20 2.4k
Jana Prausová Czechia 18 3.4k 0.9× 1.5k 1.1× 283 0.2× 117 0.1× 297 0.3× 54 4.1k
Winnie Sohn United States 13 686 0.2× 510 0.4× 173 0.1× 603 0.6× 271 0.3× 26 1.5k
Henrik C. F. Bauer Sweden 37 1.7k 0.5× 3.0k 2.2× 79 0.1× 1.7k 1.6× 205 0.2× 121 4.7k
María Eugenia Ibarrarán Viniegra Argentina 7 1.5k 0.4× 300 0.2× 539 0.4× 144 0.1× 420 0.4× 20 1.7k
Richard H. De Boer Australia 15 1.7k 0.5× 669 0.5× 426 0.3× 107 0.1× 363 0.3× 48 2.1k

Countries citing papers authored by Susie Jun

Since Specialization
Citations

This map shows the geographic impact of Susie Jun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susie Jun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susie Jun more than expected).

Fields of papers citing papers by Susie Jun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susie Jun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susie Jun. The network helps show where Susie Jun may publish in the future.

Co-authorship network of co-authors of Susie Jun

This figure shows the co-authorship network connecting the top 25 collaborators of Susie Jun. A scholar is included among the top collaborators of Susie Jun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susie Jun. Susie Jun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gupta, Vikas, Maria R. Baer, Stephen T. Oh, et al.. (2015). Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis.. Journal of Clinical Oncology. 33(15_suppl). TPS7102–TPS7102. 1 indexed citations
2.
Kuter, David J., James B. Bussel, Adrian C. Newland, et al.. (2013). Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology. 161(3). 411–423. 203 indexed citations
3.
Henry, David H., Saroj Vadhan‐Raj, Vera Hirsh, et al.. (2013). Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supportive Care in Cancer. 22(3). 679–687. 130 indexed citations
4.
5.
Yan, Xin, Lixin Shao, Wei Deng, et al.. (2013). Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis. Blood. 122(21). 1590–1590. 5 indexed citations
6.
Branstetter, Daniel, Scott D. Nelson, J. Carlos Manivel, et al.. (2012). Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone. Clinical Cancer Research. 18(16). 4415–4424. 332 indexed citations breakdown →
7.
Lipton, Allan, Karim Fizazi, Alison Stopeck, et al.. (2012). Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 48(16). 3082–3092. 420 indexed citations breakdown →
8.
Stopeck, Alison, Allan Lipton, Jean-Jacques Body, et al.. (2011). Reply to V. Fusco et al. Journal of Clinical Oncology. 29(17). e523–e524. 4 indexed citations
9.
Henry, David H., Luís Costa, François Goldwasser, et al.. (2011). Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Journal of Clinical Oncology. 29(9). 1125–1132. 877 indexed citations breakdown →
10.
Stopeck, Alison, Allan Lipton, Jean-Jacques Body, et al.. (2011). Reply to M.S. Aapro. Journal of Clinical Oncology. 29(14). e421–e423. 1 indexed citations
11.
Stopeck, Alison, Allan Lipton, Jean-Jacques Body, et al.. (2010). Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. Journal of Clinical Oncology. 28(35). 5132–5139. 1102 indexed citations breakdown →
12.
Thomas, David M., Robert M. Henshaw, Keith M. Skubitz, et al.. (2010). Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. The Lancet Oncology. 11(3). 275–280. 516 indexed citations breakdown →
13.
Kuter, David J., James B. Bussel, Adrian C. Newland, et al.. (2010). Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. Blood. 116(21). 68–68. 25 indexed citations
14.
15.
Vij, Ravi, Noemi Horvath, Andrew Spencer, et al.. (2009). An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma. American Journal of Hematology. 84(10). 650–656. 72 indexed citations
16.
Fizazi, Karim, Allan Lipton, Xavier Mariette, et al.. (2009). Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates. Journal of Clinical Oncology. 27(10). 1564–1571. 388 indexed citations
17.
Ellis, Georgiana K., Henry G. Bone, Rowan T. Chlebowski, et al.. (2008). Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer. Journal of Clinical Oncology. 26(30). 4875–4882. 342 indexed citations
18.
Lipton, Allan & Susie Jun. (2008). RANKL inhibition in the treatment of bone metastases. Current Opinion in Supportive and Palliative Care. 2(3). 197–203. 34 indexed citations
19.
Lipton, Allan, Guenther G. Steger, Jazmín Meneses Figueroa, et al.. (2008). Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy. Clinical Cancer Research. 14(20). 6690–6696. 118 indexed citations
20.
Lipton, Allan, Guenther G. Steger, Jazmín Meneses Figueroa, et al.. (2007). Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases. Journal of Clinical Oncology. 25(28). 4431–4437. 293 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ada Braun Breakdown of academic impact, for papers by Dirk J. Reitsma Breakdown of academic impact, for papers by Lawrence I. Karsh Breakdown of academic impact, for papers by Dimitra Gika Breakdown of academic impact, for papers by Michael Rader Breakdown of academic impact, for papers by Jana Prausová Breakdown of academic impact, for papers by Winnie Sohn Breakdown of academic impact, for papers by Henrik C. F. Bauer Breakdown of academic impact, for papers by María Eugenia Ibarrarán Viniegra Breakdown of academic impact, for papers by Richard H. De Boer
Rankless by CCL
2026